CHRS: Coherus BioSciences Inc. Stocks News on May 20, 2025

Coherus BioSciences First Quarter 2025 Earnings: Misses Expectations

CHRS

Simply Wall St.

6 days ago

Coherus BioSciences First Quarter 2025 Earnings: Misses Expectations

CHRS

Thomson Reuters StreetEvents

7 days ago

Q1 2025 Coherus BioSciences Inc Earnings Call

CHRS

GuruFocus.com

7 days ago

Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ...

CHRS

Zacks

7 days ago

Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates

CHRS

Associated Press Finance

7 days ago

Coherus BioSciences: Q1 Earnings Snapshot

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

CHRS

GlobeNewswire

7 days ago

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

CHRS

GuruFocus.com

11 days ago

What To Expect From Coherus BioSciences Inc (CHRS) Q1 2025 Earnings

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

CHRS

GlobeNewswire

14 days ago

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

Coherus to Participate in Upcoming Investor Conferences

CHRS

GlobeNewswire

18 days ago

Coherus to Participate in Upcoming Investor Conferences

CHRS

MT Newswires

22 days ago

Coherus BioSciences Phase 1 Trial of CHS-114 Shows Confirmed Partial Response in Cancer Patient

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

CHRS

GlobeNewswire

22 days ago

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Coherus divests Udenyca franchise to Intas for up to $558.4m

CHRS

Pharmaceutical Technology

a month ago

Coherus divests Udenyca franchise to Intas for up to $558.4m

CHRS

MT Newswires

a month ago

Coherus BioSciences Completes Sale of Udenyca Franchise to Intas Pharmaceuticals for Up to $558.4 Million

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

CHRS

GlobeNewswire

a month ago

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

CHRS

MT Newswires

2 months ago

Coherus BioSciences to Repurchase $170 Million Convertible Notes

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes

CHRS

GlobeNewswire

2 months ago

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

CHRS

GlobeNewswire

2 months ago

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

CHRS

Simply Wall St.

2 months ago

Statutory Earnings May Not Be The Best Way To Understand Coherus BioSciences' (NASDAQ:CHRS) True Position

Biotech Alert: Searches spiking for these stocks today

CHRS

TipRanks

2 months ago

Biotech Alert: Searches spiking for these stocks today

Coherus BioSciences Full Year 2024 Earnings: Beats Expectations

CHRS

Simply Wall St.

2 months ago

Coherus BioSciences Full Year 2024 Earnings: Beats Expectations

CHRS

Insider Monkey

2 months ago

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

CHRS

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Coherus BioSciences Inc Earnings Call

CHRS

GuruFocus.com

2 months ago

Coherus BioSciences Inc (CHRS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

CHRS

MT Newswires

2 months ago

Coherus BioSciences Q4 Net Loss Narrows, Revenue Declines

CHRS

Associated Press Finance

2 months ago

Coherus BioSciences: Q4 Earnings Snapshot

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

CHRS

GlobeNewswire

2 months ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

CHRS

GuruFocus.com

2 months ago

What To Expect From Coherus BioSciences Inc (CHRS) Q4 2024 Earnings

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

CHRS

GlobeNewswire

3 months ago

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

CHRS

Simply Wall St.

3 months ago

With 59% institutional ownership, Coherus BioSciences, Inc. (NASDAQ:CHRS) is a favorite amongst the big guns

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

CHRS

GlobeNewswire

3 months ago

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

CHRS

Insider Monkey

3 months ago

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

CHRS

GlobeNewswire

4 months ago

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CHRS

GlobeNewswire

4 months ago

Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

CHRS

GlobeNewswire

5 months ago

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

CHRS

MT Newswires

6 months ago

Sector Update: Health Care Stocks Decline Premarket Tuesday

CHRS

MT Newswires

6 months ago

Sector Update: Health Care

CHRS

MT Newswires

6 months ago

Coherus BioSciences to Divest Udenyca to Intas Pharmaceuticals for Up to $558 Million

Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.

CHRS

GlobeNewswire

6 months ago

Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.

Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M

CHRS

BioPharma Dive

6 months ago

Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

CHRS

GlobeNewswire

6 months ago

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

CHRS

Thomson Reuters StreetEvents

6 months ago

Q3 2024 Coherus BioSciences Inc Earnings Call

CHRS

GuruFocus.com

6 months ago

Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

CHRS

Zacks

6 months ago

Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates

CHRS

Associated Press Finance

6 months ago

Coherus BioSciences: Q3 Earnings Snapshot

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

CHRS

GlobeNewswire

6 months ago

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

CHRS

GuruFocus.com

6 months ago

Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to Know Ahead of Earnings

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

CHRS

GlobeNewswire

7 months ago

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

CHRS

GuruFocus.com

7 months ago

Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

CHRS

Insider Monkey

8 months ago

Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now

CHRS

Insider Monkey

8 months ago

Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges

CHRS

Simply Wall St.

8 months ago

Institutional owners may take dramatic actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) recent 12% drop adds to one-year losses

CHRS

MT Newswires

9 months ago

Coherus BioSciences Shares Decline After Downgrade From UBS

CHRS

MT Newswires

9 months ago

UBS Downgrades Coherus BioSciences to Neutral From Buy, Adjusts Price Target to $1.50 From $4

Coherus BioSciences Second Quarter 2024 Earnings: Beats Expectations

CHRS

Simply Wall St.

9 months ago

Coherus BioSciences Second Quarter 2024 Earnings: Beats Expectations

CHRS

Zacks

9 months ago

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

CHRS

Associated Press Finance

9 months ago

Coherus BioSciences: Q2 Earnings Snapshot

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

CHRS

GlobeNewswire

9 months ago

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

CHRS

GlobeNewswire

10 months ago

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

CHRS

MT Newswires

a year ago

Coherus BioSciences Grants Apotex License to Distribute Toripalimab in Canada

CHRS

MT Newswires

a year ago

Baird Trims Price Target on Coherus BioSciences to $8 From $9, Maintains Outperform Rating

PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar

CHRS

BioPharma Dive

a year ago

PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar

CHRS

MT Newswires

a year ago

Coherus BioSciences to Sell Yusimry to Hong Kong King-Friend Industrial in $40 Million Cash Transaction

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

CHRS

GlobeNewswire

a year ago

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

CHRS

Business Wire

a year ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

CHRS

GlobeNewswire

a year ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

CHRS

GlobeNewswire

a year ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

CHRS

Simply Wall St.

a year ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May

CHRS

Reuters

a year ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

CHRS

AFP

a year ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Enduring role of 'treasuring the past' hailed

CHRS

PR Newswire

a year ago

Enduring role of 'treasuring the past' hailed

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

CHRS

GlobeNewswire

a year ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

CHRS

GlobeNewswire

a year ago

Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

CHRS

GlobeNewswire

a year ago

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

CHRS

GlobeNewswire

a year ago

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

CHRS

GlobeNewswire

a year ago

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

CHRS

Simply Wall St.

a year ago

We Think Some Shareholders May Hesitate To Increase Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation

CHRS

MT Newswires

a year ago

Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating

Coherus BioSciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

CHRS

Simply Wall St.

a year ago

Coherus BioSciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

CHRS

Insider Monkey

a year ago

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript

CHRS

Zacks

a year ago

Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates

CHRS

Associated Press Finance

a year ago

Coherus BioSciences: Q1 Earnings Snapshot

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

CHRS

GlobeNewswire

a year ago

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

CHRS

GlobeNewswire

a year ago

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

CHRS

Simply Wall St.

a year ago

When Can We Expect A Profit From Coherus BioSciences, Inc. (NASDAQ:CHRS)?

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

CHRS

GlobeNewswire

a year ago

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

CHRS

GlobeNewswire

a year ago

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

CHRS

GlobeNewswire

a year ago

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

CHRS

Simply Wall St.

a year ago

Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five years

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

CHRS

GlobeNewswire

a year ago

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

CHRS

Insider Monkey

a year ago

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript

Coherus BioSciences Full Year 2023 Earnings: EPS Misses Expectations

CHRS

Simply Wall St.

a year ago

Coherus BioSciences Full Year 2023 Earnings: EPS Misses Expectations

Why Coherus Biosciences Stock Tumbled on Thursday

CHRS

Motley Fool

a year ago

Why Coherus Biosciences Stock Tumbled on Thursday

CHRS

Thomson Reuters StreetEvents

a year ago

Q4 2023 Coherus BioSciences Inc Earnings Call

CHRS

GuruFocus.com

a year ago

Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ...

CHRS

Associated Press Finance

a year ago

Coherus BioSciences: Q4 Earnings Snapshot

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

CHRS

GlobeNewswire

a year ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

CHRS

Simply Wall St.

a year ago

In the wake of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) latest US$49m market cap drop, institutional owners may be forced to take severe actions

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

CHRS

GlobeNewswire

a year ago

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

Coherus Completes Divestiture of Ophthalmology Franchise

CHRS

GlobeNewswire

a year ago

Coherus Completes Divestiture of Ophthalmology Franchise

Coherus BioSciences Announces New Employment Inducement Grants

CHRS

GlobeNewswire

a year ago

Latest Coherus BioSciences Inc. (CHRS) News on May 20, 2025

Share on Social Networks: